Higher versus Lower Phosphate Targets for Patients Undergoing In-Center Hemodialysis: A Randomized Controlled Trial

Daniel Edmonston^{1

2}, Tamara Isakova³, Laura M Dember⁴, Sophia Waymyers², Davy Andersen², Kevin E Chan⁵, Hrishikesh Chakraborty², Myles Wolf^{1

2

6}

Affiliations

¹ Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
² Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
³ Division of Nephrology, Department of Medicine, Center for Translational Metabolism and Health, Institute of Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
⁴ Renal, Electrolyte and Hypertension Division, Department of Medicine, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
⁵ National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland.
⁶ Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, New York.

Daniel Edmonston et al. J Am Soc Nephrol. 2025.

. 2025 Jul 10.

doi: 10.1681/ASN.0000000765. Online ahead of print.

Daniel Edmonston^{1

2}, Tamara Isakova³, Laura M Dember⁴, Sophia Waymyers², Davy Andersen², Kevin E Chan⁵, Hrishikesh Chakraborty², Myles Wolf^{1

2

6}

¹ Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
² Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
³ Division of Nephrology, Department of Medicine, Center for Translational Metabolism and Health, Institute of Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
⁴ Renal, Electrolyte and Hypertension Division, Department of Medicine, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
⁵ National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland.
⁶ Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, New York.

No abstract available

Keywords: chronic hemodialysis; hyperphosphatemia; mineral metabolism.

References

1. United States Renal Data System. 2022 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2023.
1. Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238–248. doi: 10.1056/NEJMoa043545 - DOI
1. Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395–1407. doi: 10.1056/NEJMoa0810177 - DOI
1. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181–2192. doi: 10.1016/s0140-6736(11)60739-3 - DOI
1. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31(4):607–617. doi: 10.1053/ajkd.1998.v31.pm9531176 - DOI